Biolife solutions stock.

Based on the share price being above its 5, 20 & 50 day exponential moving averages, the current trend is considered strongly bullish and BLFS is experiencing ...Nov 8, 2023 · Biolife Solutions stock has received a consensus rating of buy. The average rating score is and is based on 8 buy ratings, 0 hold ratings, and 0 sell ratings. What was the 52-week low for Biolife ... Get the latest BioLife Solutions Inc (BLFS) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment …Cold Chain Solutions. Cold Chain Shippers. ... Stock. CONTACT. BioLife Solutions Inc. 3303 Monte Villa Parkway, Suite 310, Bothell, WA 98021 USA ...

BioLife Solutions Reports First Quarter 2023 Financial Results. Revenue of $37.7 million increased 4% over Q1 2022, ex-COVID growth of 16% and biopreservation media revenue growth of 28%. Q1 2023 ...BioLife Solutions, Inc. develops, manufactures, and supplies bioproduction tools and services for the cell and gene therapy industry in the United States, Canada, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.

BioLife recently disclosed its financial results for the fourth quarter of 2022, showcasing solid revenue growth and a better gross margin. In Q4 2022, the company brought in $44.3 million in ...Management will provide an overview of the Company's financial results and a general business update. To access the webcast, log onto the Investor Relations ...

Wall Street Stock Market & Finance report, prediction for the future: You'll find the Biolife Solutions share forecasts, stock quote and buy / sell signals below. According to present data Biolife Solutions's BLFS shares and potentially its market environment have been in bearish cycle last 12 months (if exists). BioLife Solutions, Inc. (NASDAQ:BLFS – Get Rating) major shareholder Casdin Partners Master Fund, L acquired 15,000 shares of BioLife Solutions stock in a transaction on Tuesday, May 16th.The shares were bought at an average price of $20.19 per share, for a total transaction of $302,850.00. Following the purchase, the insider now …View the latest BioLife Solutions Inc. (BLFS) stock price, news, historical charts, analyst ratings and financial information from WSJ.BioLife will issue 6,646,870 shares of common stock for 100% of the outstanding shares of Stirling in an all-stock transaction, which is expected to close early in the second quarter of 2021. With Stirling, BioLife believes that total GAAP revenue in 2021 will exceed $100 million and the transaction is expected to be accretive on an adjusted ...

Nov 8, 2023 · Biolife Solutions stock has received a consensus rating of buy. The average rating score is and is based on 8 buy ratings, 0 hold ratings, and 0 sell ratings. What was the 52-week low for Biolife ...

Stock analysis for BioLife Solutions Inc (BLFS:NASDAQ CM) including stock price, stock chart, company news, key statistics, fundamentals and company profile.

BioLife Solutions Stock Forecast. All Analysts Top Analysts Stock Price Forecast. According to 5 stock analysts, the average 12-month stock price forecast for BLFS stock stock is $26, which predicts an increase of 99.62%. The lowest target is $23 and the highest is $29. On average, analysts rate BLFS stock stock as a strong buy.Stock Price Forecast. According to 5 stock analysts, the average 12-month stock price forecast for BLFS stock stock is $26, which predicts an increase of 99.62%. The lowest target is $23 and the highest is $29. On average, analysts rate BLFS stock stock as a strong buy.BioLife Solutions, Inc. (BLFS) Stock Price, News, Quote & History - Yahoo Finance Canada markets close in 5 hours 5 minutes S&P/TSX 20,174.44 +60.48(+0.30%) S&P …BioLife Solutions Inc stock performance at a glance. Check BioLife Solutions Inc’s past financial performance, like revenue or net income, plus the top level summary of its past and current market value.Dec 4, 2023 · Biolife Solutions Inc (NASDAQ:BLFS) has a beta value of 1.60 and has seen 2.24 million shares traded in the last trading session. The company, currently valued at $596.91M, closed the last trade at $13.25 per share which meant it gained $0.88 on the day or 7.11% during that session. The BLFS stock ... If you’re just getting started, tracking investments might seem like a mystery. Thankfully, modern tools and technology make it easier than ever to figure out how to manage your stock portfolio and to track it. This quick guide gives you ti...

BioLife Solutions is trading near 52-week lows as its growth story has floundered and profitability remains uncertain. Learn why I rate BLFS stock a hold.Mar 13, 2023 · BioLife Solutions, Inc. (BLFS) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? By taking a look at the ... BOTHELL, Wash., Jan. 5, 2021 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of a portfolio of class-defining bioproduction ...BioLife Solutions, Inc. reaffirmed 2023 revenue guidance for the fiscal 2023. For the period, the company expects revenue to range from $188 million to $202 million, reflecting year-over-year growth...Consensus BioLife Solutions, Inc. Equities. BLFS. US09062W2044. Market Closed - Nasdaq. Other stock markets.BioLife Solutions, Inc. develops, manufactures, and supplies bioproduction tools and services for the cell and gene therapy industry in the United States, Canada, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.

BioLife Solutions, Inc. develops, manufactures, and supplies bioproduction tools and services for the cell and gene therapy industry in the United States, Canada, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.BioLife Solutions: Overcoming Challenges and Primed for Growth – An Optimistic Buy Recommendation Amid Revenue Surpassing Expectations and Anticipated Divestiture TipRanks 18d

--BioLife Solutions, Inc., ... BioLife will issue 6,646,870 shares of common stock for 100% of the outstanding shares of Stirling in an all-stock transaction, which is expected to close early in ...BOTHELL, Wash., Aug. 9, 2022 /PRNewswire/ -- BioLife Solutions, Inc. (Nasdaq: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of class-defining bioproduction products and services for the cell and gene therapies ("CGT") and the broader biopharma markets, today announced financial results for the three and six months ended ...BioLife Solutions, Inc. develops, manufactures, and supplies bioproduction tools and services for the cell and gene therapy industry in the United States, Canada, Europe, the Middle East, Africa, and internationally. The company’s products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.Biolife Solutions stocks price quote with latest real-time prices, charts, financials, latest news, technical analysis and opinions. ... Do the numbers hold clues to what lies ahead for the stock? BLFS: 20.37 (-0.97%) APYX: 5.06 (+1.81%) BioLife Solutions Reports First Quarter 2023 Financial Results PR Newswire - Wed May 10, 3:03PM CDTShares of BioLife Solutions, Inc. (NASDAQ:BLFS) have received a favorable rating from five investment analysts, according to Bloomberg. These analysts Favorable Analyst Ratings and Growth Potential in BioLife Solutions, Inc. - Best StocksBroadridge Corporate Issuer Solutions, Inc. P.O. Box 1342 Brentwood, New York 11717 USA (877) 830 - 4936 [email protected] daily share price chart and data for BioLife Solutions since 1992 adjusted for splits and dividends. The latest closing stock price for BioLife Solutions as of …Supplier: BIOLIFE SOLUTIONS INC 210373. This item has a minimum qty of 4 per supplier requirements. The CryoStor series of cell-specific, optimized freeze media, is designed to prepare and preserve cells in ultra low temperature environments (-70C to -196C). CryoStor CS10, pre-formulated with 10% DMSO, provides a safe, protective environment ...BioLife Solutions Reports First Quarter 2023 Financial Results. Revenue of $37.7 million increased 4% over Q1 2022, ex-COVID growth of 16% and biopreservation media revenue growth of 28%. Q1 2023 ...... Stock, $0.001 par value of BioLife Solutions, Inc. shall be filed on behalf of the undersigned. November 27, 2020. (Date). Casdin Capital, LLC. By: /s/ Eli ...

May 9, 2023 · Biolife Solutions will release earnings for Q1 on May 10. Wall Street predict expect Biolife Solutions will release losses per share of $0.213. Go here to watch Biolife Solutions stock price in ...

Mar 22, 2021 · BioLife will issue 6,646,870 shares of common stock for 100% of the outstanding shares of Stirling in an all-stock transaction, which is expected to close early in the second quarter of 2021. With Stirling, BioLife believes that total GAAP revenue in 2021 will exceed $100 million and the transaction is expected to be accretive on an adjusted ...

BOTHELL, Wash., Dec. 19, 2022 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading supplier of class-defining bioproduction tools and services for the cell and gene therapies ("CGT") and broader biopharma markets, today announced plans to announce preliminary 2022 revenue and introduce 2023 revenue guidance before market open on ...BioLife Solutions is introducing initial 2023 revenue guidance, which is based on expectations for its existing business. Expected growth rates are all based on preliminary unaudited revenue. Total revenue for 2023 is expected to range from $188 million to $202 million, reflecting year-over-year growth of 16% to 25%. Excluding COVID related ...of class-defining solutions. Solutions. Our platforms enable significant improvement in shelf life and post-preservation viability and function of biologic materials. Cell Processing. ... BioLife Solutions Inc. 3303 Monte Villa Parkway, Suite 310, Bothell, WA 98021 USA; T +1.866.424.6543 or 425.402.1400; F +1.425.402.1433 ...The estimated net worth of Roderick de Greef is at least $463,582.14 as of November 30th, 2022. Mr. de Greef owns 34,314 shares of BioLife Solutions stock worth more than $463,582 as of November 20th. This net worth estimate does not reflect any other investments that Mr. de Greef may own.2.70% of BioLife Solutions stock is owned by insiders. Learn more on BLFS's insider holdings. Which BioLife Solutions insiders have been buying company stock? The following insider purchased BLFS shares in the last 24 months: Casdin Partners Master Fund, L ($12,648,274.13).Dec 1, 2023 · BioLife Solutions (NASDAQ:BLFS) and Zynex (NASDAQ:ZYXI) are both small-cap medical companies, but which is the superior stock?We will contrast the two companies based on the strength of their dividends, risk, earnings, profitability, valuation, analyst recommendations, institutional ownership, media sentiment and community ranking. BioLife Solutions, Inc. : News, information and stories for BioLife Solutions, Inc. | Other OTC: | Other OTCBOTHELL, Wash., Aug. 8, 2023 /PRNewswire/ -- BioLife Solutions, Inc. (Nasdaq: BLFS) ("BioLife" or the "Company"), a leading supplier of class-defining bioproduction tools and services for the cell ...Culture supplement to replace FBS or AB Serum. Biodefined composition reduces lot-to-lot variability. Supports a wide range of cell types including MSCs, T-Cells, NK Cells, Endothelial cells, and more. Promotes improved in vitro and In vivo cell quality in CAR-T applications. Typically used at concentrations ranging from 2% to 10%.

Historical daily share price chart and data for BioLife Solutions since 1992 adjusted for splits and dividends. The latest closing stock price for BioLife Solutions as of …BOTHELL, Wash., March 22, 2021 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of a portfolio of class-defining bioproduction products and services for cell and gene therapies, today announced the signing of a definitive merger agreement to acquire Global Cooling, Inc., operating as …BOTHELL, Wash., Aug. 8, 2019 / PRNewswire / -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer and supplier of a portfolio of best in class bioproduction tools for cell and gene therapies, today announced that it has executed a share exchange agreement to effect the acquisition of SAVSU Technologies, a leading developer of advanced ...Instagram:https://instagram. us stock moversoklahoma gas and electric stock pricesites like robinhooddoes state farm have motorcycle insurance CryoStor®CS10 effectively mitigates temperature-induced molecular cell stress responses to maximize post-thaw viability and recovery for a variety of immune cell types, including T cells (data not shown) and B cells. Here, human B cells from 6 different donors cryopreserved in CryoStor®CS10 show reproducibly high viability after thawing, as ... cv3 financial servicesnasdaq achv Biolife Solutions Dividends FAQ. Does Biolife Solutions pay a dividend? No, BLFS has not paid a dividend within the past 12 months. If you're new to stock ... qqqy stock $26.0 ( 109.85% upside) Analyst Consensus: Strong Buy Stock ForecastsThe estimated net worth of Roderick de Greef is at least $463,582.14 as of November 30th, 2022. Mr. de Greef owns 34,314 shares of BioLife Solutions stock worth more than $463,582 as of November 20th. This net worth estimate does not reflect any other investments that Mr. de Greef may own.BioLife Sciences is a commercialization accelerator, licensor and developer of innovative and disruptive technologies for the healthcare, beauty and food and beverage industry sectors. 2831 Saint Rose Parkway Suite 200 Henderson, NV 89052 United States